In this CRA Insights, the authors Will Foster, Kees Chamberlain, Joanne Clark, and Carl Lottig recount the recent scientific and technological advances in drug development in the central nervous system (CNS). CNS disorders impose a significant burden on patients, with the global impact on CNS disorders growing significantly. However, the treatment for many CNS major disorders is still limited to the management of symptoms, and numerous rare neurological disorders lack any indicated treatments at all. There is a significant and urgent unmet need for new disease modifying treatments (DMTs) that target the underlying pathophysiology.
Despite the challenges, there has been many innovative CNS therapies launched over the past decade, and the authors provide an overview of these developments in science, ecosystem, and investments that hope to support the new wave of innovation in CNS treatments over the coming decade.
Read more about the drug development for the central nervous system.
